These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 30561106

  • 1. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
    Kawamura S, Iinuma H, Wada K, Takahashi K, Minezaki S, Kainuma M, Shibuya M, Miura F, Sano K.
    J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
    Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F, Sano K.
    J Hepatobiliary Pancreat Sci; 2018 Feb; 25(2):155-161. PubMed ID: 29130611
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R, Iinuma H, Dejima H, Sakai T, Uehara H, Matsutani N, Kawamura M.
    Oncology; 2018 Feb; 94(5):311-323. PubMed ID: 29533963
    [Abstract] [Full Text] [Related]

  • 4. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
    Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A, Utsumi T, Sato H, Iwama T, Ijiri M, Sakatani A, Tanaka K, Nomura Y, Ueno N, Kashima S, Moriichi K, Mizukami Y, Kohgo Y, Okumura T.
    BMC Cancer; 2018 Jan 31; 18(1):116. PubMed ID: 29385987
    [Abstract] [Full Text] [Related]

  • 5. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M.
    Cancer Lett; 2017 May 01; 393():86-93. PubMed ID: 28232049
    [Abstract] [Full Text] [Related]

  • 6. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, Onishi H, Oda Y, Goggins M, Nakamura M.
    Ann Surg Oncol; 2019 Jul 01; 26(7):2104-2111. PubMed ID: 30820789
    [Abstract] [Full Text] [Related]

  • 7. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A, Procházka V, Hlavsa J, Kiss I, Srovnal J, Kala Z, Slabý O.
    Klin Onkol; 2019 Jul 01; 32(Suppl 1):174-176. PubMed ID: 31064193
    [Abstract] [Full Text] [Related]

  • 8. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer.
    Chen J, Yao D, Chen W, Li Z, Guo Y, Zhu F, Hu X.
    Int J Biol Markers; 2022 Mar 01; 37(1):74-80. PubMed ID: 35001683
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma.
    Takeda Y, Yamada D, Kobayashi S, Sasaki K, Iwagami Y, Tomimaru Y, Noda T, Takahashi H, Asaoka T, Shimizu J, Doki Y, Eguchi H.
    PLoS One; 2024 Mar 01; 19(9):e0310328. PubMed ID: 39288140
    [Abstract] [Full Text] [Related]

  • 10. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z, Ma T, Huang B, Lin L, Zhou Y, Yan J, Zou Y, Chen S.
    J Exp Clin Cancer Res; 2019 Jul 15; 38(1):310. PubMed ID: 31307515
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.
    Clin Cancer Res; 2012 Jan 15; 18(2):534-45. PubMed ID: 22114136
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
    Chen Y, Zhu H, Wang Y, Song Y, Zhang P, Wang Z, Gao J, Li Z, Du Y.
    Technol Cancer Res Treat; 2019 Jan 01; 18():1533033818824314. PubMed ID: 30803373
    [Abstract] [Full Text] [Related]

  • 15. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
    Tsukamoto M, Iinuma H, Yagi T, Matsuda K, Hashiguchi Y.
    Oncology; 2017 Jan 01; 92(6):360-370. PubMed ID: 28376502
    [Abstract] [Full Text] [Related]

  • 16. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.
    Ann Surg; 2022 Jan 01; 275(1):e229-e237. PubMed ID: 32398486
    [Abstract] [Full Text] [Related]

  • 17. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
    Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH.
    Oncol Rep; 2014 Mar 01; 31(3):1157-64. PubMed ID: 24398877
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
    Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, Liu Z, Wei X, Röder C, Trauzold A, Kalthoff H, Zheng S.
    Oncotarget; 2017 Feb 28; 8(9):15159-15167. PubMed ID: 28122349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.